The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer

Cancer Treat Res. 2000:103:57-75. doi: 10.1007/978-1-4757-3147-7_4.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use*
  • Antibody Specificity
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / immunology
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / therapy*
  • Clinical Trials, Phase II as Topic
  • Combined Modality Therapy
  • Drug Design
  • Drug Interactions
  • Female
  • Forecasting
  • Gene Amplification*
  • Gene Expression Regulation, Neoplastic*
  • Genes, erbB-2*
  • Growth Substances / physiology
  • Humans
  • Immunization, Passive*
  • Immunoglobulin Fc Fragments / immunology
  • Mice
  • Neoplasm Metastasis
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / biosynthesis
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / immunology
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Growth Substances
  • Immunoglobulin Fc Fragments
  • Neoplasm Proteins
  • Receptor, ErbB-2
  • Trastuzumab